Pathogenesis and Treatment of Hemophilia View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2017-06-15

AUTHORS

Keiji Nogami , Midori Shima

ABSTRACT

Hemophilia A and B are congenital inherited bleeding disorders, occurred by genetic abnormalities of blood coagulation factor (F)VIII and FIX molecules, respectively. The clinical abnormality is associated with bleeding episodes affecting especially joints and muscles, and repeated hemorrhage results in chronic arthropathy finally associated with loss of joint movement. The current hemostatic treatment is the replacement therapy of plasma-derived or recombinant (r)FVIII or FIX concentrates with on demand or prophylaxis. Development of this therapy had improved the quality of life of hemophiliacs more dramatically than before. The primary and secondary prophylaxis is recently becoming widespread for the prevention of arthropathy. There remain some issues such as frequent intravenous injection, however. Extended half-life rFVIII and rFIX concentrates have been recently developed, and some products are available. However, in 20–30% of severe hemophilia A and 3–5% of hemophilia B which had multi-transfused, anti-FVIII (FIX) alloantibodies (inhibitors) appeared, resulting in difficulty of hemostatic management. Immune tolerance induction therapy to eradicate inhibitors has been actively conducted. The bypassing agent therapy is treated for hemophilia patients with inhibitor. Subcutaneous injection therapy such as FVIII-mimetic bispecific antibody or gene therapy is currently ongoing in the clinical trials for the future prospective therapy. More... »

PAGES

189-204

Book

TITLE

Hematological Disorders in Children

ISBN

978-981-10-3885-3
978-981-10-3886-0

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-981-10-3886-0_9

DOI

http://dx.doi.org/10.1007/978-981-10-3886-0_9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090690554


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nogami", 
        "givenName": "Keiji", 
        "id": "sg:person.0603447532.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603447532.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shima", 
        "givenName": "Midori", 
        "id": "sg:person.0705772523.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705772523.06"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-06-15", 
    "datePublishedReg": "2017-06-15", 
    "description": "Hemophilia A and B are congenital inherited bleeding disorders, occurred by genetic abnormalities of blood coagulation factor (F)VIII and FIX molecules, respectively. The clinical abnormality is associated with bleeding episodes affecting especially joints and muscles, and repeated hemorrhage results in chronic arthropathy finally associated with loss of joint movement. The current hemostatic treatment is the replacement therapy of plasma-derived or recombinant (r)FVIII or FIX concentrates with on demand or prophylaxis. Development of this therapy had improved the quality of life of hemophiliacs more dramatically than before. The primary and secondary prophylaxis is recently becoming widespread for the prevention of arthropathy. There remain some issues such as frequent intravenous injection, however. Extended half-life rFVIII and rFIX concentrates have been recently developed, and some products are available. However, in 20\u201330% of severe hemophilia A and 3\u20135% of hemophilia B which had multi-transfused, anti-FVIII (FIX) alloantibodies (inhibitors) appeared, resulting in difficulty of hemostatic management. Immune tolerance induction therapy to eradicate inhibitors has been actively conducted. The bypassing agent therapy is treated for hemophilia patients with inhibitor. Subcutaneous injection therapy such as FVIII-mimetic bispecific antibody or gene therapy is currently ongoing in the clinical trials for the future prospective therapy.", 
    "editor": [
      {
        "familyName": "Ishii", 
        "givenName": "Eiichi", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-981-10-3886-0_9", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-981-10-3885-3", 
        "978-981-10-3886-0"
      ], 
      "name": "Hematological Disorders in Children", 
      "type": "Book"
    }, 
    "keywords": [
      "hemophilia A", 
      "immune tolerance induction therapy", 
      "prevention of arthropathy", 
      "tolerance induction therapy", 
      "subcutaneous injection therapy", 
      "frequent intravenous injections", 
      "severe haemophilia A", 
      "quality of life", 
      "anti-FVIII alloantibodies", 
      "treatment of hemophilia", 
      "blood coagulation factors", 
      "secondary prophylaxis", 
      "induction therapy", 
      "chronic arthropathy", 
      "hemorrhage results", 
      "injection therapy", 
      "agent therapy", 
      "hemostatic treatment", 
      "replacement therapy", 
      "haemophilia patients", 
      "hemostatic management", 
      "prospective therapies", 
      "clinical trials", 
      "intravenous injection", 
      "clinical abnormalities", 
      "rFIX concentrates", 
      "coagulation factors", 
      "FIX molecules", 
      "therapy", 
      "bispecific antibodies", 
      "genetic abnormalities", 
      "hemophilia B", 
      "prophylaxis", 
      "arthropathy", 
      "joint movement", 
      "abnormalities", 
      "gene therapy", 
      "treatment", 
      "inhibitors", 
      "alloantibodies", 
      "hemophiliacs", 
      "patients", 
      "pathogenesis", 
      "hemophilia", 
      "trials", 
      "prevention", 
      "antibodies", 
      "disorders", 
      "muscle", 
      "episodes", 
      "injection", 
      "joints", 
      "management", 
      "factors", 
      "life", 
      "loss", 
      "concentrate", 
      "quality", 
      "difficulties", 
      "development", 
      "movement", 
      "results", 
      "molecules", 
      "products", 
      "issues", 
      "fixes", 
      "demand"
    ], 
    "name": "Pathogenesis and Treatment of Hemophilia", 
    "pagination": "189-204", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090690554"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-981-10-3886-0_9"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-981-10-3886-0_9", 
      "https://app.dimensions.ai/details/publication/pub.1090690554"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_284.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-981-10-3886-0_9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-981-10-3886-0_9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-981-10-3886-0_9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-981-10-3886-0_9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-981-10-3886-0_9'


 

This table displays all metadata directly associated to this object as RDF triples.

133 TRIPLES      22 PREDICATES      91 URIs      84 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-981-10-3886-0_9 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Na293bf56f16d494a966730a9b95a5e93
4 schema:datePublished 2017-06-15
5 schema:datePublishedReg 2017-06-15
6 schema:description Hemophilia A and B are congenital inherited bleeding disorders, occurred by genetic abnormalities of blood coagulation factor (F)VIII and FIX molecules, respectively. The clinical abnormality is associated with bleeding episodes affecting especially joints and muscles, and repeated hemorrhage results in chronic arthropathy finally associated with loss of joint movement. The current hemostatic treatment is the replacement therapy of plasma-derived or recombinant (r)FVIII or FIX concentrates with on demand or prophylaxis. Development of this therapy had improved the quality of life of hemophiliacs more dramatically than before. The primary and secondary prophylaxis is recently becoming widespread for the prevention of arthropathy. There remain some issues such as frequent intravenous injection, however. Extended half-life rFVIII and rFIX concentrates have been recently developed, and some products are available. However, in 20–30% of severe hemophilia A and 3–5% of hemophilia B which had multi-transfused, anti-FVIII (FIX) alloantibodies (inhibitors) appeared, resulting in difficulty of hemostatic management. Immune tolerance induction therapy to eradicate inhibitors has been actively conducted. The bypassing agent therapy is treated for hemophilia patients with inhibitor. Subcutaneous injection therapy such as FVIII-mimetic bispecific antibody or gene therapy is currently ongoing in the clinical trials for the future prospective therapy.
7 schema:editor Ned8912c809af431e8fe75cb35043cc23
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nc550121fd4e047b1ab4c496f3a55471d
11 schema:keywords FIX molecules
12 abnormalities
13 agent therapy
14 alloantibodies
15 anti-FVIII alloantibodies
16 antibodies
17 arthropathy
18 bispecific antibodies
19 blood coagulation factors
20 chronic arthropathy
21 clinical abnormalities
22 clinical trials
23 coagulation factors
24 concentrate
25 demand
26 development
27 difficulties
28 disorders
29 episodes
30 factors
31 fixes
32 frequent intravenous injections
33 gene therapy
34 genetic abnormalities
35 haemophilia patients
36 hemophilia
37 hemophilia A
38 hemophilia B
39 hemophiliacs
40 hemorrhage results
41 hemostatic management
42 hemostatic treatment
43 immune tolerance induction therapy
44 induction therapy
45 inhibitors
46 injection
47 injection therapy
48 intravenous injection
49 issues
50 joint movement
51 joints
52 life
53 loss
54 management
55 molecules
56 movement
57 muscle
58 pathogenesis
59 patients
60 prevention
61 prevention of arthropathy
62 products
63 prophylaxis
64 prospective therapies
65 quality
66 quality of life
67 rFIX concentrates
68 replacement therapy
69 results
70 secondary prophylaxis
71 severe haemophilia A
72 subcutaneous injection therapy
73 therapy
74 tolerance induction therapy
75 treatment
76 treatment of hemophilia
77 trials
78 schema:name Pathogenesis and Treatment of Hemophilia
79 schema:pagination 189-204
80 schema:productId N99c57437cd774168b2e7e22966fff441
81 Nf5c04d963cc5485fa905a0b9e8d4208c
82 schema:publisher Nf61536d7a82c444ca769a8b8f9a157f2
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090690554
84 https://doi.org/10.1007/978-981-10-3886-0_9
85 schema:sdDatePublished 2022-11-24T21:15
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher N63ec7bb036b449759bd7dbe2061d6960
88 schema:url https://doi.org/10.1007/978-981-10-3886-0_9
89 sgo:license sg:explorer/license/
90 sgo:sdDataset chapters
91 rdf:type schema:Chapter
92 N330ca4bac82646c8aa8f991da3fe32c1 rdf:first sg:person.0705772523.06
93 rdf:rest rdf:nil
94 N63ec7bb036b449759bd7dbe2061d6960 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N73b343bb97cd40c981ad54a141d09ba4 schema:familyName Ishii
97 schema:givenName Eiichi
98 rdf:type schema:Person
99 N99c57437cd774168b2e7e22966fff441 schema:name doi
100 schema:value 10.1007/978-981-10-3886-0_9
101 rdf:type schema:PropertyValue
102 Na293bf56f16d494a966730a9b95a5e93 rdf:first sg:person.0603447532.27
103 rdf:rest N330ca4bac82646c8aa8f991da3fe32c1
104 Nc550121fd4e047b1ab4c496f3a55471d schema:isbn 978-981-10-3885-3
105 978-981-10-3886-0
106 schema:name Hematological Disorders in Children
107 rdf:type schema:Book
108 Ned8912c809af431e8fe75cb35043cc23 rdf:first N73b343bb97cd40c981ad54a141d09ba4
109 rdf:rest rdf:nil
110 Nf5c04d963cc5485fa905a0b9e8d4208c schema:name dimensions_id
111 schema:value pub.1090690554
112 rdf:type schema:PropertyValue
113 Nf61536d7a82c444ca769a8b8f9a157f2 schema:name Springer Nature
114 rdf:type schema:Organisation
115 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
116 schema:name Medical and Health Sciences
117 rdf:type schema:DefinedTerm
118 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
119 schema:name Clinical Sciences
120 rdf:type schema:DefinedTerm
121 sg:person.0603447532.27 schema:affiliation grid-institutes:grid.410814.8
122 schema:familyName Nogami
123 schema:givenName Keiji
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603447532.27
125 rdf:type schema:Person
126 sg:person.0705772523.06 schema:affiliation grid-institutes:grid.410814.8
127 schema:familyName Shima
128 schema:givenName Midori
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705772523.06
130 rdf:type schema:Person
131 grid-institutes:grid.410814.8 schema:alternateName Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan
132 schema:name Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara, Nara, Japan
133 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...